University Hospital of Pisa
This sponsor has funded 3 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 29263 | Planned | ExPloring efficAcy, safeTy, and adHerence oF dIsease-modifyiNg antirheumatic Drugs through trajEctoRy model: the PATHFINDER study | No | No |
| 38705 | Planned | Diagnostic delay, drug utilization and clinical effectiveness and safety outcomes in patients with Crohn’s disease: checKing and AssessIng Real wOrld... | No | No |
| 43705 | Planned | Impact of diagnostic delay on drug utilization and use of healthcare facilities in patients with ulcerative colitis: observational study on real-world... | No | No |
PAS by Risk Management Plan (RMP) requirement
University Hospital of Pisa
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
University Hospital of Pisa
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
University Hospital of Pisa
1 Study countries specified are the following:
- Italy